Top 5 Drug Type | Count |
---|---|
Small molecule drug | 5 |
Therapeutic radiopharmaceuticals | 2 |
Chemical drugs | 1 |
Antibody drug conjugate (ADC) | 1 |
Radiolabeled antibody | 1 |
Target- |
Mechanism Anion transport proteins modulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. AU |
First Approval Date24 Oct 2017 |
Target |
Mechanism Tubulin inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date17 Jun 2010 |
Target |
Mechanism PSMA inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. EU [+3] |
First Approval Date27 Nov 1995 |
Start Date06 Jan 2021 |
Sponsor / Collaborator |
Start Date07 Aug 2019 |
Sponsor / Collaborator |
Start Date30 Jan 2018 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Astodrimer sodium | Bacterial Vaginosis More | Approved |
Irinotecan Hydrochloride ( TOP1 ) | Colorectal Cancer More | Phase 2 |
Cabazitaxel Acetone ( Tubulin ) | Solid tumor More | Phase 2 |
Docetaxel ( Tubulin ) | Neoplasms More | Phase 2 |
AZD-0466 ( Bcl-2 x Bcl-xl ) | Neoplasms More | Clinical |